Author:
Nakazawa Hideyuki,Sakai Kaoko,Sudo Yuriko,Iwabuchi Ryohei,Sakai Hitoshi,Nishina Sayaka,Kawakami Toru,Kawakami Fumihiro,Matsuzawa Shuji,Ito Toshiro,Kitahara Mari,Kamijo Yuji,Umemura Takeji,Ushiki Atsuhito,Kanai Shinichiro,Tsuchiya Hiroyuki,Ishida Fumihiro
Subject
Transplantation,Immunology,Immunology and Allergy
Reference43 articles.
1. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine;Gavriatopoulou;Clin. Exp. Med.,2021
2. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study;Tartof;Lancet,2021
3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months;Thomas;N. Engl. J. Med.,2021